This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (11) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Rahman, A Articles by Hiepe, F Search for Related Content PubMed PubMed Citation Articles by Rahman, A Articles by Hiepe, F Pubmed/NCBI databases Medline Plus Health Information Lupus Social Bookmarking                         What's this?

Anti-DNA antibodies - overview of assays and clinical correlations

Centre for Rheumatology, Department of Medicine, University College London, London, UK; Centre for Rheumatology, Arthur Stanley House, 40–50 Tottenham Street, London W1T 4NJ, UK.; anisur.rahman{at}ucl.ac.uk

F Hiepe

Medizinische Klinik III, Charite Humboldt University, Schumannstrasse 20=21, D-10117 Berlin, Germany

Many authors have studied the links between levels of anti-dsDNA antibodies and disease activity in patients with SLE. Interpretationof these studies must take into account the facts that there are a range of possible assays for anti-dsDNA and a number of indices available for assessing disease activity. A recent study compared levels of various autoantibodies with organ specific disease activity assessed during the British Isles Lupus Assessment Group (BILAG) index. Amti-dsDNA and anti-heparan sulphate levels were more likely to be raised in patients with renal than non-renal disease.

Some anti-DNA antibodies are actually anti-nucleosome antibodies, which lose DNA reactivity when purified under dissociating conditions. Patients with SLE have significantly increased levels of nucleosomes in their sera compared with healthy controls. In patients with SLE, reduced clearance of nucleosomes released from apoptotic cells may induce the formation of antinucleosome antibodies.

Key Words: anti-DNA • nucleosome • disease activity • apoptosis

Lupus, Vol. 11, No. 12, 770-773 (2002)
DOI: 10.1191/0961203302lu313rp


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A Souza, L. da Silva, F. Oliveira, A. Roselino, and P Louzada-Junior Anti-nucleosome and anti-chromatin antibodies are present in active systemic lupus erythematosus but not in the cutaneous form of the disease Lupus, March 1, 2009; 18(3): 223 - 229. [Abstract] [PDF]

				A. Buhl, J. H. Metzger, N. H. H. Heegaard, P. von Landenberg, M. Fleck, and P. B. Luppa Novel Biosensor-Based Analytic Device for the Detection of Anti-Double-Stranded DNA Antibodies Clin. Chem., February 1, 2007; 53(2): 334 - 341. [Abstract] [Full Text] [PDF]

				H-P Jaekel, A Trabandt, N Grobe, and E Werle Anti-dsDNA antibody subtypes and anti-C1q antibodies: toward a more reliable diagnosis and monitoring of systemic lupus erythematosus and lupus nephritis Lupus, June 1, 2006; 15(6): 335 - 345. [Abstract] [PDF]

				J. A. Simon, J. Cabiedes, E. Ortiz, J. Alcocer-Varela, and J. Sanchez-Guerrero Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker Rheumatology, February 1, 2004; 43(2): 220 - 224. [Abstract] [Full Text] [PDF]